QL-315

N/A

Report date: 2026/03/19 17:03:23

Base Information

Drug NameQL-315

Drug Alias NameQL-315

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers

Mechanisms of ActionLeucine-rich repeat-containing protein 15 inhibitorsT cell surface glycoprotein CD3 stimulants

TargetsLeucine-rich repeat-containing protein 15T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesQlsf Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesQlsf Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A